Background The prognosis of gastric cancer patients with positive HER-2 is poor, and there is a lack of reports on tumor markers related to positive HER-2 in gastric cancer.
Objective To investigate the correlation between serum CYFRA21-1 expression and HER-2 positive gastric cancer patients.
Methods From January 2019 to December 2021, 165 gastric cancer patients, including 115 males and 50 females, aged from 29 to 82 years, were enrolled in this study. The CYFRA21-1 level of patients with positive HER-2 gene expression was analyzed. The ROC curve of CYFRA21-1 expression in HER-2 positive patients was drawn to analyze the threshold of predicting HER-2 positive gastric cancer.
Results Serum CYFRA21-1 level was correlated with histopathological differentiation and classification of gastric cancer, TNM stage and tumor size (P<0.05). The level of CYFRA21-1 in HER-2 positive group was significantly higher than that in negative group (P=0.038). The OR value of CYFRA21-1 in the positive HER-2 group was 3.529 (0.967-12.878), and the prediction percentage of positive HER-2 gastric cancer patients was 70.4%. When the cutoff value of CYFRA21-1 was 3.60 ng/mL, the sensitivity and specificity of positive HER-2 prediction in gastric cancer patients would reach the highest, which were 0.552 and 0.833, respectively. The 1-year, 2-year and 3-year survival rates of gastric cancer patients with CYFRA21-1<3.62 ng/mL were higher than those with CYFRA21-1>3.62 ng/mL (P=0.0024). The 1-year, 2-year and 3-year survival rates of HER-2 negative gastric cancer patients were higher than those of positive patients (P=0.0442).
Conclusion The expression levels of HER-2 gene and sera CYFRA21-1 increase in patients with gastric cancer metastasis, large tumor and late TNM stage. The survival prognosis of patients with high CYFRA21-1 level and positive HER-2 is poor. High sera CYFRA21-1 level has a good warning effect on positive HER-2 gene in gastric cancer patients.
DownLoad: